JP2001508430A5 - - Google Patents

Download PDF

Info

Publication number
JP2001508430A5
JP2001508430A5 JP1998530400A JP53040098A JP2001508430A5 JP 2001508430 A5 JP2001508430 A5 JP 2001508430A5 JP 1998530400 A JP1998530400 A JP 1998530400A JP 53040098 A JP53040098 A JP 53040098A JP 2001508430 A5 JP2001508430 A5 JP 2001508430A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998530400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001508430A (ja
Filing date
Publication date
Priority claimed from US08/779,767 external-priority patent/US6737057B1/en
Application filed filed Critical
Publication of JP2001508430A publication Critical patent/JP2001508430A/ja
Publication of JP2001508430A5 publication Critical patent/JP2001508430A5/ja
Ceased legal-status Critical Current

Links

JP53040098A 1997-01-07 1998-01-07 免疫抑制因子のエンドサイトーシスによる提示のための化合物、組成物及び方法 Ceased JP2001508430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/779,767 US6737057B1 (en) 1997-01-07 1997-01-07 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US08/779,767 1997-01-07
PCT/US1998/000520 WO1998030706A1 (en) 1997-01-07 1998-01-07 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors

Publications (2)

Publication Number Publication Date
JP2001508430A JP2001508430A (ja) 2001-06-26
JP2001508430A5 true JP2001508430A5 (enExample) 2005-09-08

Family

ID=25117492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53040098A Ceased JP2001508430A (ja) 1997-01-07 1998-01-07 免疫抑制因子のエンドサイトーシスによる提示のための化合物、組成物及び方法

Country Status (6)

Country Link
US (2) US6737057B1 (enExample)
EP (1) EP1012308A1 (enExample)
JP (1) JP2001508430A (enExample)
AU (1) AU744885B2 (enExample)
CA (1) CA2277582A1 (enExample)
WO (1) WO1998030706A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
EP1093464A2 (en) * 1998-07-06 2001-04-25 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
EP1104456A1 (en) * 1998-08-10 2001-06-06 Chiron Corporation Engineered antigen-presenting cells expressing an array of antigens and uses thereof
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
EP1598370A3 (en) * 1999-10-27 2006-05-10 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
EP1223958A4 (en) * 1999-10-27 2004-07-21 Cel Sci Corp PREPARATION METHODS AND COMPOUNDS OF PEPTIDE CONSTRUCTIONS CONCERNING THE TREATMENT OF AUTOIMMUNE AND. TRANSPLANTATION-RELATED "HOST VERSUS GRAFT" PATHOGENESE PROPERTIES
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
JP2004509978A (ja) * 2000-06-05 2004-04-02 ユニバーシティ　オブ　テネシー　コーポレイション 免疫抑制因子のエンドサイトーシスによる提示のための組成物及び方法
ATE368475T1 (de) 2000-06-29 2007-08-15 Emd Lexigen Res Ct Corp Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DK1383785T3 (da) 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
ATE554787T1 (de) 2002-04-09 2012-05-15 Univ Missouri Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US7744876B2 (en) * 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8603471B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
WO2003099312A1 (en) * 2002-05-27 2003-12-04 Östergötlands Läns Landsting Method for determining immune system affecting compounds
DK1572748T3 (da) 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
JP4937132B2 (ja) 2004-12-09 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫原性の低下したｉｌ−７変種
EP1875246B1 (en) * 2005-04-15 2016-10-05 CanImGuide Therapeutics AB Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6
ES2608803T3 (es) 2007-05-08 2017-04-17 Canimguide Therapeutics Ab Estructuras inmunorreguladoras procedentes de proteínas naturales
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
LT3107563T (lt) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Gliko-nukreipiantys terapiniai agenai
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
AU616338B2 (en) 1989-02-02 1991-10-24 Mato Maschinen- Und Metallwarenfabrik Curt Matthaei Gmbh & Co Kg Belt skimming device
DE69023900T4 (de) * 1989-02-24 1996-10-02 The Regents Of The University Of California, Berkeley, Calif. Gentechnologisch veränderte immunglobuline.
US5612035A (en) 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5969109A (en) 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
JPH06511241A (ja) 1991-09-23 1994-12-15 ジェネンテク，インコーポレイテッド 自己免疫疾患の診断および治療
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
AU3220593A (en) 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
WO1994014847A1 (en) 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
CA2218858A1 (en) 1995-05-02 1996-11-07 Alexion Pharmaceuticals Inc. Modified myelin protein molecules
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
WO1999009064A1 (en) 1997-08-19 1999-02-25 Mount Sinai School Of Medicine Of New York University ; Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules

Similar Documents

Publication Publication Date Title
JP2000509942A5 (enExample)
JP2000509635A5 (enExample)
JP2000509637A5 (enExample)
JP2000510751A5 (enExample)
JP2000509912A5 (enExample)
JP2000507042A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2001508430A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510247A5 (enExample)
JP2000510969A5 (enExample)
JP2000508102A5 (enExample)
JP2000508836A5 (enExample)
JP2000509818A5 (enExample)
JP2000509520A5 (enExample)
JP2000507434A5 (enExample)